Literature DB >> 15229789

Pathophysiology of myasthenia gravis.

Benjamin W Hughes1, Maria Luisa Moro De Casillas, Henry J Kaminski.   

Abstract

Myasthenia gravis (MG) is arguably the best understood autoimmune disease, and its study has also led to fundamental appreciation of mechanisms of neuromuscular transmission. MG is caused by antibodies against the acetylcholine receptor (AChR), which produce a compromise in the end-plate potential, reducing the safety factor for effective synaptic transmission. It is clear that AChR antibody destruction of the postsynaptic surface is dependent on complement activation. A muscle-specific kinase has been recently found to be an antigenic target in MG patients without antibodies against the AChR. Autoantibody production in MG is a T-cell-dependent process, but how a breakdown in tolerance occurs is not known. In MG there is an interesting differential involvement of muscle groups, in particular, the extraocular muscles. This article reviews normal neuromuscular transmission, mechanisms of the autoimmune process of MG, and differential susceptibility of eye muscles to MG.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15229789     DOI: 10.1055/s-2004-829585

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  24 in total

1.  Identification of novel MicroRNA signatures linked to experimental autoimmune myasthenia gravis pathogenesis: down-regulated miR-145 promotes pathogenetic Th17 cell response.

Authors:  Jiao Wang; Shuangshuang Zheng; Ning Xin; Changxin Dou; Linlin Fu; Xiuying Zhang; Jing Chen; Yanyan Zhang; Deqin Geng; Chenghua Xiao; Guiyun Cui; Xia Shen; Yang Lu; Jinhua Wang; Ruiguo Dong; Yuehua Qiao; Yong Zhang
Journal:  J Neuroimmune Pharmacol       Date:  2013-09-17       Impact factor: 4.147

2.  Molecular biomarkers in glaucoma.

Authors:  Sanjoy K Bhattacharya; Richard K Lee; Franz H Grus
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-07       Impact factor: 4.799

3.  Selection of a human butyrylcholinesterase-like antibody single-chain variable fragment resistant to AChE inhibitors from a phage library expressed in E. coli.

Authors:  Adriano Podestà; Serena Rossi; Ilaria Massarelli; Sara Carpi; Barbara Adinolfi; Stefano Fogli; Anna Maria Bianucci; Paola Nieri
Journal:  MAbs       Date:  2014 Jul-Aug       Impact factor: 5.857

Review 4.  IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.

Authors:  Isabel Illa
Journal:  J Neurol       Date:  2005-05       Impact factor: 4.849

5.  Identification of the neuromuscular junction transcriptome of extraocular muscle by laser capture microdissection.

Authors:  Caroline Ketterer; Ulrike Zeiger; Murat T Budak; Neal A Rubinstein; Tejvir S Khurana
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-14       Impact factor: 4.799

6.  Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats.

Authors:  J Chamberlain-Banoub; J W Neal; M Mizuno; C L Harris; B P Morgan
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

7.  The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice.

Authors:  B P Morgan; J Chamberlain-Banoub; J W Neal; W Song; M Mizuno; C L Harris
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

8.  Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3+ regulatory T-cell profile.

Authors:  Huan Yang; Yong Zhang; Minghua Wu; Jing Li; Wenbin Zhou; Guiyuan Li; Xiaoling Li; Bo Xiao; Premkumar Christadoss
Journal:  Inflamm Res       Date:  2009-09-19       Impact factor: 4.575

Review 9.  Immunological mechanisms in glaucoma.

Authors:  F Grus; D Sun
Journal:  Semin Immunopathol       Date:  2008-03-11       Impact factor: 9.623

10.  Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis.

Authors:  Jian Rong Sheng; Liang Cheng Li; Balaji B Ganesh; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Clin Immunol       Date:  2008-05-27       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.